Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: A systematic review and meta-analysis

J. Lee, S. Hahn, D. W. Kim, J. Kim, S. N. Kang, S. Y. Rha, K. B. Lee, J. H. Kang, B. J. Park

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Background:Although chemotherapeutic regimens containing a taxane or platinum agent have been widely recommended for unfavourable carcinoma of unknown primary (CUP), no evidence exists for the superiority of any administered regimens. To date, the efficacy has been mostly assessed in the limited setting of phase II trials, and few attempts have been made to synthesise all available data for survival outcomes.Methods:Electronic databases were searched from 1980 to 2011. Survival results were combined for each pre-specified category of regimens using a random-effects model, and meta-regression models were used to adjust for heterogeneity in some known prognostic factors.Results:A total of 32 studies were included for meta-analysis. Tendency towards better survival outcome by platinums or taxanes was indicated. After adjustment for important prognostic factors, however, the difference between the platinum-based and non-platinum regimens became no longer significant. Survival benefits by the taxane-based regimens remained significant, with a prolonged median survival time of 1.52 months (P=0.03) and a higher 1-year survival rate of 6.25% (P=0.05), but the benefit did not sustain for 2 years.Conclusion:Although no effective therapies have been established, this meta-analysis helps to fill an important gap of evidence. However, caution should still be taken because of the potential unmeasured confounding.

Original languageEnglish
Pages (from-to)39-48
Number of pages10
JournalBritish journal of cancer
Volume108
Issue number1
DOIs
Publication statusPublished - 2013 Jan 15

Fingerprint

Taxoids
Platinum
Meta-Analysis
Carcinoma
Databases
taxane
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lee, J. ; Hahn, S. ; Kim, D. W. ; Kim, J. ; Kang, S. N. ; Rha, S. Y. ; Lee, K. B. ; Kang, J. H. ; Park, B. J. / Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary : A systematic review and meta-analysis. In: British journal of cancer. 2013 ; Vol. 108, No. 1. pp. 39-48.
@article{7068089cb5c94da0a16622b3696406ff,
title = "Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: A systematic review and meta-analysis",
abstract = "Background:Although chemotherapeutic regimens containing a taxane or platinum agent have been widely recommended for unfavourable carcinoma of unknown primary (CUP), no evidence exists for the superiority of any administered regimens. To date, the efficacy has been mostly assessed in the limited setting of phase II trials, and few attempts have been made to synthesise all available data for survival outcomes.Methods:Electronic databases were searched from 1980 to 2011. Survival results were combined for each pre-specified category of regimens using a random-effects model, and meta-regression models were used to adjust for heterogeneity in some known prognostic factors.Results:A total of 32 studies were included for meta-analysis. Tendency towards better survival outcome by platinums or taxanes was indicated. After adjustment for important prognostic factors, however, the difference between the platinum-based and non-platinum regimens became no longer significant. Survival benefits by the taxane-based regimens remained significant, with a prolonged median survival time of 1.52 months (P=0.03) and a higher 1-year survival rate of 6.25{\%} (P=0.05), but the benefit did not sustain for 2 years.Conclusion:Although no effective therapies have been established, this meta-analysis helps to fill an important gap of evidence. However, caution should still be taken because of the potential unmeasured confounding.",
author = "J. Lee and S. Hahn and Kim, {D. W.} and J. Kim and Kang, {S. N.} and Rha, {S. Y.} and Lee, {K. B.} and Kang, {J. H.} and Park, {B. J.}",
year = "2013",
month = "1",
day = "15",
doi = "10.1038/bjc.2012.516",
language = "English",
volume = "108",
pages = "39--48",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary : A systematic review and meta-analysis. / Lee, J.; Hahn, S.; Kim, D. W.; Kim, J.; Kang, S. N.; Rha, S. Y.; Lee, K. B.; Kang, J. H.; Park, B. J.

In: British journal of cancer, Vol. 108, No. 1, 15.01.2013, p. 39-48.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary

T2 - A systematic review and meta-analysis

AU - Lee, J.

AU - Hahn, S.

AU - Kim, D. W.

AU - Kim, J.

AU - Kang, S. N.

AU - Rha, S. Y.

AU - Lee, K. B.

AU - Kang, J. H.

AU - Park, B. J.

PY - 2013/1/15

Y1 - 2013/1/15

N2 - Background:Although chemotherapeutic regimens containing a taxane or platinum agent have been widely recommended for unfavourable carcinoma of unknown primary (CUP), no evidence exists for the superiority of any administered regimens. To date, the efficacy has been mostly assessed in the limited setting of phase II trials, and few attempts have been made to synthesise all available data for survival outcomes.Methods:Electronic databases were searched from 1980 to 2011. Survival results were combined for each pre-specified category of regimens using a random-effects model, and meta-regression models were used to adjust for heterogeneity in some known prognostic factors.Results:A total of 32 studies were included for meta-analysis. Tendency towards better survival outcome by platinums or taxanes was indicated. After adjustment for important prognostic factors, however, the difference between the platinum-based and non-platinum regimens became no longer significant. Survival benefits by the taxane-based regimens remained significant, with a prolonged median survival time of 1.52 months (P=0.03) and a higher 1-year survival rate of 6.25% (P=0.05), but the benefit did not sustain for 2 years.Conclusion:Although no effective therapies have been established, this meta-analysis helps to fill an important gap of evidence. However, caution should still be taken because of the potential unmeasured confounding.

AB - Background:Although chemotherapeutic regimens containing a taxane or platinum agent have been widely recommended for unfavourable carcinoma of unknown primary (CUP), no evidence exists for the superiority of any administered regimens. To date, the efficacy has been mostly assessed in the limited setting of phase II trials, and few attempts have been made to synthesise all available data for survival outcomes.Methods:Electronic databases were searched from 1980 to 2011. Survival results were combined for each pre-specified category of regimens using a random-effects model, and meta-regression models were used to adjust for heterogeneity in some known prognostic factors.Results:A total of 32 studies were included for meta-analysis. Tendency towards better survival outcome by platinums or taxanes was indicated. After adjustment for important prognostic factors, however, the difference between the platinum-based and non-platinum regimens became no longer significant. Survival benefits by the taxane-based regimens remained significant, with a prolonged median survival time of 1.52 months (P=0.03) and a higher 1-year survival rate of 6.25% (P=0.05), but the benefit did not sustain for 2 years.Conclusion:Although no effective therapies have been established, this meta-analysis helps to fill an important gap of evidence. However, caution should still be taken because of the potential unmeasured confounding.

UR - http://www.scopus.com/inward/record.url?scp=84872603775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872603775&partnerID=8YFLogxK

U2 - 10.1038/bjc.2012.516

DO - 10.1038/bjc.2012.516

M3 - Review article

C2 - 23175147

AN - SCOPUS:84872603775

VL - 108

SP - 39

EP - 48

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -